153 related articles for article (PubMed ID: 20415570)
1. Changing sociodemographic and clinical characteristics of tuberculosis among HIV-infected patients, New York City, 1992-2005.
Harris TG; Li J; Hanna DB; Munsiff SS
Clin Infect Dis; 2010 Jun; 50(11):1524-31. PubMed ID: 20415570
[TBL] [Abstract][Full Text] [Related]
2. The emergence of drug-resistant tuberculosis in New York City.
Frieden TR; Sterling T; Pablos-Mendez A; Kilburn JO; Cauthen GM; Dooley SW
N Engl J Med; 1993 Feb; 328(8):521-6. PubMed ID: 8381207
[TBL] [Abstract][Full Text] [Related]
3. Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease.
Grau I; Ardanuy C; Liñares J; Podzamczer D; Schulze MH; Pallares R
HIV Med; 2009 Sep; 10(8):488-95. PubMed ID: 19459987
[TBL] [Abstract][Full Text] [Related]
4. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
Hung CC; Hung MN; Hsueh PR; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Huang YT; Lo YC; Hsiao CF; Chang SC
Clin Infect Dis; 2007 Sep; 45(5):e60-7. PubMed ID: 17682981
[TBL] [Abstract][Full Text] [Related]
5. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
Li J; Munsiff SS; Driver CR; Sackoff J
Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
[TBL] [Abstract][Full Text] [Related]
6. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
[TBL] [Abstract][Full Text] [Related]
7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
8. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
9. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
10. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART.
Muga R; Ferreros I; Langohr K; de Olalla PG; Del Romero J; Quintana M; Alastrue I; Belda J; Tor J; Pérez-Hoyos S; Del Amo J;
AIDS; 2007 Nov; 21(18):2521-7. PubMed ID: 18025889
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and outcome of human immunodeficiency virus-infected patients with sporadic multidrug-resistant tuberculosis in New York City.
Mannheimer SB; Sepkowitz KA; Stoeckle M; Friedman CR; Hafner A; Riley LW
Int J Tuberc Lung Dis; 1997 Aug; 1(4):319-25. PubMed ID: 9432387
[TBL] [Abstract][Full Text] [Related]
13. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
[TBL] [Abstract][Full Text] [Related]
14. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy.
Dheda K; Lampe FC; Johnson MA; Lipman MC
J Infect Dis; 2004 Nov; 190(9):1670-6. PubMed ID: 15478074
[TBL] [Abstract][Full Text] [Related]
15. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
16. A continuing survey of drug-resistant tuberculosis, New York City, April 1994.
Fujiwara PI; Cook SV; Rutherford CM; Crawford JT; Glickman SE; Kreiswirth BN; Sachdev PS; Osahan SS; Ebrahimzadeh A; Frieden TR
Arch Intern Med; 1997 Mar; 157(5):531-6. PubMed ID: 9066457
[TBL] [Abstract][Full Text] [Related]
17. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
[TBL] [Abstract][Full Text] [Related]
18. Trends in drug-resistant Mycobacterium tuberculosis in New York City, 1991-2003.
Munsiff SS; Li J; Cook SV; Piatek A; Laraque F; Ebrahimzadeh A; Fujiwara PI
Clin Infect Dis; 2006 Jun; 42(12):1702-10. PubMed ID: 16705575
[TBL] [Abstract][Full Text] [Related]
19. Transmission trends for human immunodeficiency virus associated tuberculosis in New York City.
Geng EH; Kreiswirth BN; Burzynski J; Schluger NW
Int J Tuberc Lung Dis; 2005 Jun; 9(6):661-6. PubMed ID: 15971394
[TBL] [Abstract][Full Text] [Related]
20. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
